XLRN Acceleron Pharma Inc.

24.47
+0.07  (0.28%)
Previous Close 24.40
Open 24.46
Price To book 4.01
Market Cap 923.64M
Shares 37,746,000
Volume 326,854
Short Ratio 5.09
Av. Daily Volume 416,232

SEC filingsSee all SEC filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17536706
  2. 8-K - Current report 17516383
  3. 8-K - Current report 162039187
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 161971904
  5. 8-K - Current report 161971651

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 updated data at ASH 2016.
Luspatercept
Low or intermediate-risk MDS patients who are erythropoiesis-stimulating agent (ESA) naïve or ring sideroblast negative (RS-)
Phase 3 enrollment to be completed 2H 2017.
Luspatercept - MEDALIST
Myelodysplastic syndromes (MDS) cancer
Phase 3 enrollment to be completed 2H 2017.
Luspatercept - BELIEVE
b -thalassemia
Phase 2 dosing initiation announced December 22, 2016. Open label initial data due late 2017, with randomized part of trial to be initiated in 2018.
ACE-083
Facioscapulohumeral muscular dystrophy
Phase 2 preliminary data due 2H 2017.
Dalantercept - DART Study
Renal Cell Carcinoma (RCC) - cancer

Latest News

  1. ACCELERON PHARMA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  2. Top Insider Buys Highlight for Week of Jan. 6
  3. Acceleron Outlines Corporate Goals and Priorities for 2017
  4. Acceleron Outlines Corporate Goals and Priorities for 2017
  5. Former CEO of Finish Line Inc. (FINL) Sells Shares as Underperformance Persists; Other Notable Insider Transactions
  6. Acceleron to Webcast Presentation at 35th Annual J.P. Morgan Healthcare Conference
  7. Acceleron Announces First Patient Treated in Phase 2 Trial of ACE-083 in Facioscapulohumeral Muscular Dystrophy
  8. Acceleron Announces First Patient Treated in Phase 2 Trial of ACE-083 in Facioscapulohumeral Muscular Dystrophy
  9. Coverage initiated on Acceleron Pharma by Oppenheimer
  10. ACCELERON PHARMA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  11. Acceleron and Celgene Announce Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia Presented at the 58th Annual Meeting of the American Society of Hematology
  12. Celgene, Acceleron Launch Blood Disorder Study (CELG)
  13. Acceleron, Celgene Present Myelodysplastic Syndromes Data
  14. Acceleron and Celgene Announce Preliminary Results from an Investigator Initiated Phase 2 Study of Sotatercept in Myelofibrosis at the 58th Annual Meeting of the American Society of Hematology
  15. Acceleron, Celgene Seek to Replace Entrenched Anti-Anemia Drugs in MDS Treatment
  16. Acceleron and Celgene Announce Updated Results from Ongoing Phase 2 Studies of Luspatercept in Myelodysplastic Syndromes at the 58th Annual Meeting of the American Society of Hematology
  17. ETFs with exposure to Acceleron Pharma, Inc. : December 2, 2016
  18. Acceleron Pharma to Host Conference Call and Webcast to Review Data Presented at the 58th American Society of Hematology Annual Meeting and Exposition
  19. Acceleron Pharma, Inc. breached its 50 day moving average in a Bearish Manner : XLRN-US : December 1, 2016
  20. Acceleron Pharma to Host Conference Call and Webcast to Review Data Presented at the 58th American Society of Hematology Annual Meeting and Exposition

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17536706
  2. 8-K - Current report 17516383
  3. 8-K - Current report 162039187
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 161971904
  5. 8-K - Current report 161971651
  6. 8-K - Current report 161904512
  7. 8-K - Current report 161881375
  8. CT ORDER - Confidential treatment order 161814028
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 161808256
  10. 8-K - Current report 161805706